SCHEMBL3757030

SCHEMBL3757030

N#Cc1c(F)cc(Br)cc1N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.60
KDM4E B2RXH2 6/20 0.60
HPGD P15428 4/20 0.60
HSD17B10 Q99714 2/20 0.60
MAPK1 P28482 2/20 0.44
KHK P50053 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 2/20 0.39
CCR5 P51681 1/20 0.38
MAPT P10636 2/20 0.36
TSHR P16473 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NSD2 O96028 1/20 0.36
CASP1 P29466 1/20 0.36
HTT P42858 1/20 0.36
CASP7 P55210 1/20 0.36
CASP6 P55212 1/20 0.36
USP30 Q70CQ3 1/20 0.36
SLC6A9 P48067 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24984459 0.82 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL22964415 0.81 KDM4E (0.38) ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL3759033 0.79 CCR5 (0.42) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL5105409 0.76 KDM4E (0.55) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL29599792 0.75 KDM4E (1.00) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL823501 0.75 KDM4E (1.00) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL578753 0.73 PDE3B (0.46) ALDH1A1KDM4EHPGDHSD17B10KMT2A
SCHEMBL2795825 0.72 CCR5 (0.52) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL29508149 0.72 SLC6A5 (0.55) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL3122343 0.72 SLC6A5 (0.55) ALDH1A1KDM4EHPGDHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150232429-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE 2015-08-20 US disclosed
US-9018205-B2 Substituted pyrimidinyl-amines as protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2015-04-28 US disclosed
EP-2200436-B1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS SCRIPPS RESEARCH INST (US) 2015-01-21 EP disclosed
US-8530480-B2 Substituted pyrimidinyl-amines as protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-10 US disclosed
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-05 US disclosed
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2010-11-25 US disclosed
EP-2200436-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS The Scripps Research Institute (US) 2010-06-30 EP disclosed
WO-2009032861-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 ALDH1A1 4097/4885KDM4E 2345/4885HPGD 2191/4885
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 ALDH1A1 4097/4885KDM4E 2345/4885HPGD 2191/4885
US-20150232429-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 ALDH1A1 4097/4885KDM4E 2345/4885HPGD 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.